Rivastigmine in apathetic but dementia and depression-free patients with Parkinson's disease: A double-blind, placebo-controlled, randomised clinical trial

Journal of Neurology, Neurosurgery and Psychiatry

Volumn 85, Issue 6, 2014, Pages 668-674

  Devos, David ^a,b   Moreau, Caroline ^a,b   Maltête, David ^c   Lefaucheur, Romain ^c   Kreisler, Alexandre ^a,d   Eusebio, Alexandre ^e   Defer, Gilles ^f   Ouk, Thavarak ^a,b   Azulay, Jean Philippe ^e   Krystkowiak, Pierre ^g,h   Witjas, Tatiana ^e   Delliaux, Marie ^a   Destée, Alain ^a,d   Duhamel, Alain ^b   Bordet, Régis ^a,b   Defebvre, Luc ^a,b   Dujardin, Kathy ^a,b  

^a LILLE UNIVERSITY HOSPITAL   (France)

^b UNIV LILLE   (France)

^c ROUEN UNIVERSITY HOSPITAL   (France)

^d JEAN PIERRE AUBERT RESEARCH CENTER   (France)

^e TIMONE HOSPITAL   (France)

^f CAEN UNIVERSITY HOSPITAL   (France)

^g UNIVERSITÉ DE PICARDIE JULES VERNE   (France)

^h AMIENS UNIVERSITY HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; RIVASTIGMINE;

AGED; APATHY; ARTICLE; ASTHENIA; CAREGIVER BURDEN; CONTROLLED STUDY; DAILY LIFE ACTIVITY; DEMENTIA; DEPRESSION; DOUBLE BLIND PROCEDURE; DROWSINESS; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DYSKINESIA; FAINTNESS; FEMALE; HEADACHE; HUMAN; LILLE APATHY RATING SCALE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NIGHTMARE; ORTHOSTATIC HYPOTENSION; PARKINSON DISEASE; PARKINSONISM; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; SUDDEN DEATH; URINE RETENTION;

3521 WORDS (ABSTRACT:237 WORDS); 79 CHARACTERS (SUBTITLE:61 CHARACTERS); FIGURE:1 (FLOWCHART); REFERENCES:29; RUNNING TITLE:47 CHARACTERS; TABLES:3;

ACTIVITIES OF DAILY LIVING; ADULT; AGED; APATHY; CHOLINESTERASE INHIBITORS; DEMENTIA; DEPRESSION; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; NEUROPROTECTIVE AGENTS; PARKINSON DISEASE; PHENYLCARBAMATES; PROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX;

EID: 84899929969     PISSN: 00223050     EISSN: 1468330X     Source Type: Journal    
DOI: 10.1136/jnnp-2013-306439     Document Type: Article

References (29)

1. Marin RS. Apathy: a neuropsychiatric syndrome. J Neuropsychiatry Clin Neurosci 1991;3:243-54.
2. Aarsland D, Marsh L, Schrag A. Neuropsychiatric symptoms in Parkinson's disease. Mov Disord 2009;24:2175-86.
3. Dujardin K, Sockeel P, Devos D, et al. Characteristics of apathy in Parkinson's disease. Mov Disord 2007;22:778-84. (Pubitemid 46800097)
4. Wise RA. Dopamine, learning and motivation. Nat Rev Neurosci 2004;5:483-94. (Pubitemid 38715515)
5. Thobois S, Ardouin C, Lhommée E, et al. Non-motor dopamine withdrawal syndrome after surgery for Parkinson's disease: predictors and underlying mesolimbic denervation. Brain 2010;133:1111-27.
6. Czernecki V, Schüpbach M, Yaici S, et al. Apathy following subthalamic stimulation in Parkinson disease: a dopamine responsive symptom. Mov Disord 2008;23:964-9.
7. Thobois S, Lhommée E, Klinger H, et al. Parkinsonian apathy responds to dopaminergic stimulation of D2/D3 receptors with piribedil. Brain 2013;136:1568-77.
8. Le Jeune F, Drapier D, Bourguignon A, et al. Subthalamic nucleus stimulation in Parkinson disease induces apathy: a PET study. Neurology 2009;73:1746-51.
9. Dujardin K, Sockeel P, Delliaux M, et al. Apathy may herald cognitive decline and dementia in Parkinson's disease. Mov Disord 2009;24:2391-7.
10. Zgaljardic DJ, Foldi NS, Borod JC. Cognitive and behavioral dysfunction in Parkinson's disease: neurochemical and clinicopathological contributions. J Neural Transm 2004;111:1287-301. (Pubitemid 39468391)
11. Cummings JL, Back C. The cholinergic hypothesis of neuropsychiatric symptoms in Alzheimer's disease. Am J Geriatr Psychiatry. 1998;6:S64-78.
12. Cummings JL. Toward a molecular neuropsychiatry of neurodegenerative diseases. Ann Neurol 2003;54:147-54. (Pubitemid 36909613)
13. Emre M, Aarsland D, Albanese A, et al. Rivastigmine for dementia associated with Parkinson's disease. N Engl J Med 2004;351:2509-18. (Pubitemid 39603164)
14. Dujardin K, Devos D, Duhem S, et al. Utility of the Mattis dementia rating scale to assess the efficacy of rivastigmine in dementia associated with Parkinson's disease. J Neurol 2006;253:1154-9. (Pubitemid 44511471)
15. Sockeel P, Dujardin K, Devos D, et al. The Lille Apathy rating scale, a new instrument for detecting and quantifying apathy: validation in Parkinson's disease. J Neurol Neurosurg Psychiatry 2006;77:579-84. (Pubitemid 43844578)
16. Leentjens AF, Dujardin K, Marsh L, et al. Apathy and anhedonia rating scales in Parkinson's disease: critique and recommendations. Mov Disord 2008;23:2004-14.
17. Gibb WRG, Lees AJ. The prevalence of the lewy body to the pathogenesis of idiopathic Parkinson 's disease. J Neurol Neurosurg Psychiatry 1988;51:745-52.
18. Robert P, Onyike CU, Leentjens AF, et al. Proposed diagnostic criteria for apathy in Alzheimer's disease and other neuropsychiatric disorders. Eur Psychiatry 2009;24:98-104.
19. Emre M, Aarsland D, Brown R, et al. Clinical diagnostic criteria for dementia associated with Parkinson's disease. Mov Disord 2007;22:1689-707. (Pubitemid 47597592)
20. Hérbert R, Bravo G, Préville M. Reliability, validity, and reference values of the Zarit Burden Interview for assessing informal caregivers of community-dwelling older persons with dementia. Can J Aging 2000;19:494-507. (Pubitemid 32155573)
21. Lawton MP, Brody EM. Assessment of older people: self-maintaining and instrumental activities of daily living. Gerontologist 1969;93:179-86.
22. Jenkinson C, Fitzpatrick R, Peto V, et al. The Parkinson's Disease Questionnaire (PDQ-39): development and validation of a Parkinson's disease summary index score. Age Ageing 1997;26:353-7. (Pubitemid 27448379)
23. Johns MW. A new method for measuring daytime sleepiness: the Epworth sleepiness scale. Sleep 1991;14:540-5.
24. Cook RD. Influential observations in linear regression. J Am Stat Assoc 1979;74:169-74.
25. Cohen J. A power primer. Psychol Bull 1992;112:155-9.
26. Moreau C, Delval A, Defebvre L, et al.; Parkgait-II study group. Methylphenidate for gait hypokinesia and freezing in patients with Parkinson 's disease undergoing subthalamic stimulation: a multicentre, parallel, randomised, placebo-controlled trial. Lancet Neurol 2012;11:589-96.
27. Chatterjee A, Fahn S. Methylphenidate treats apathy in Parkinson's disease. J Neuropsychiatry Clin Neurosci 2002;14:461-2.
28. Starkstein SE. Apathy in Parkinson's disease: diagnostic and etiological dilemmas. Mov Disord 2012;27:174-8.
29. Winblad B, Grossberg G, Frolich L, et al. "IDEAL: a 6-month, double-blind, placebo-controlled study of the first skin patch for Alzheimer disease". Neurology 2007;69:S14-22. (Pubitemid 47205655)